Examples of using Biosimilar in English and their translations into Spanish
{-}
-
Colloquial
-
Official
Representatives from the leading medical societies took part in the conference with a view to outlining each one's stance with regard to biosimilar drugs.
15th November 2016 the 5th World Biosimilar Congress was held in Basel Switzerland.
A study conducted by the consultancy company GFK on behalf of the European Biosimilars Group analysed the main factors that support a sustainable European biosimilar drugs market GfK Market Access.
For this reason, she is calling for strategies to promote the use of biosimilar drugs, in order to reduce economic expenditure.
To finish off the year, mAbxience received the Biosimilar Initiative of the Year Award 2016 awarded by the prestigious magazine Generics Bulletin within the framework of the Global Generics& Biosimilars Awards.
Clinical studies on a biosimilar do not seek to establish the clinical safety
The biosimilar has previously been shown to have a similar molecular structure
not it is biosimilar.
obtained with Rituximab Biosimilar combined with CHOP 1 in patients with Diffuse Large B-Cell Lymphoma DLBCL.
the World Biosimilar Congress Europe 2016,
in 2014, the first plant with a monoclonal antibody biosimilar produced integrally in Argentina.
obtained with Rituximab Biosimilar in combination with CHOP in patients with diffuse large B-cell non-Hodgkin's lymphoma LDCBG.
However, one of the questions to arise with the arrival of biosimilars on the market is whether doctors can substitute the original biological drug that is being administered for a biosimilar, or if they can be used interchangeably.
67% of consumers were not sure what a biosimilar was, and 16% chose an incorrect response to the question about what a biosimilar was PwC Health Research Institute, December 2015.
such as the batch number and the establishment to which the biosimilar being used belongs.
the name of the biosimilar and the regulations on extrapolating indications have not always been well defined in all countries.
A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorized original biological medicinal product(reference medicinal product)
One of the main problems that biosimilar drugs face is that many doctors
When the biosimilar has proven to be comparable to the reference in terms of its physicochemical and structural characteristics
The regulatory authorities approve a biosimilar based on safety,